Руководство по диагностике, лечению и профилактике хронических гепатитов b и c в первичном звене здравоохранения Этапы оказания помощи
|
|
Health Technol Assess 2004;8(39). Nobili et al. The role of lifestyle changes in the management of chronic liver disease. BMC Medicine 2011, 9:70 Thomas R. Riley III, M.D., M.S., and Аhsan M. Bhatti, M.D. Preventive Strategies in Chronic Liver Disease: Part I. Alcohol,Vaccines, Toxic Medications and Supplements, Diet and Exercise. American family physician volume 64, number 9 / november 1, 2001 Konishi I, Hiasa Y, Tokumoto Y, Abe M, Furukawa S, Toshimitsu K, Matsuura B, Onji M. Aerobic exercise improves insulin resistance and decreases body fat and serum levels of leptin in patients with hepatitis C virus. Hepatol Res. 2011 Oct;41(10):928-35. doi: 10.1111/j.1872-034X.2011.00833.x. Epub 2011 Jun 28. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, Lindsay KL, Lok AS, Di Bisceglie AM, Lee WM, Ghany MG; HALT-C Trial Group Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology. 2008 Feb;47(2):605-12. Payen JL, Pillard F, Mascarell V, Rivière D, Couzigou P, Kharlov N. Is physical activity possible and beneficial for patients with hepatitis C receiving pegylated interferon and ribavirin therapy? Gastroenterol Clin Biol. 2009 Jan;33(1 Pt 1):8-14. Epub 2008 Dec 12. Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Wong DK, Cheung AM, O’Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta analysis. Ann Intern Med 1993;119:312–323. Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008; 48 (Suppl. 1): S2–S19. Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R,Piratvisuth T, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007;56:699–705. Fried MW, Piratvisuth T, Lau GKK, Marcellin P, Chow WC,Cooksley G, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg- positive chronic hepatitis B. Hepatology 2008;47:428–434. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186–194. Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007;46: 1695–1703. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT,Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5years. Gastroenterology 2006;131:1743–1751. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV; GLOBE Study Group. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009 Feb;136(2):486-95. Epub 2008 Nov 1. Jiang H, Wang J, Zhao W. Lamivudine versus telbivudine in the treatment of chronic hepatitis B: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2012 Aug 17. Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL. HBV 99-01 Study Group. Treatment with Peginterferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101:297–303. Anstee, Q.M., Day, C.P., S-Adenosylmethionine (SAMe) Therapy in Liver Disease: A Review of Current Evidence and Clinical Utility, Journal of Hepatology (2012), Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007;45:1056–1075. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507–539. Chevaliez S, Bouvier-Alias M, Laperche S, Pawlotsky JM. Performance of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. J Clin Microbiol 2008;46:1716–1723. Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandao- Mello CE, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha 2b a randomized trial. Ann Intern Med 2009;150:W97–W528.
70.Dhiman RK, Chawla YK. Dig Dis Sci. Herbal medicines for liver diseases 2005 Oct;50(10):1807-12 |
